Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)

Diagnostic Microbiology and Infectious Disease

Volumn 37, Issue 2, 2000, Pages 139-142

  Deshpande, L M ^a   Jones, R N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; DILUTION; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-INFECTIVE AGENTS; BACTERIA; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; NEISSERIACEAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0034079148     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(00)00124-3     Document Type: Article

References (16)

1. Andrews J.M., Ashby J.P., Jevon G.M., Wise R. Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria. J Antimicrob Chemother. 44:1999;819-822.
2. Baron, E. J., & Murray, P. R. Bacteriology. In Murray, P. R., Barron, E. J., Pfaller, M. A., Tenover, F. C., & Yolken, R. H. (Eds) Manual of Clinical Microbiology, 6th ed. (pp. 246-662.) Washington, DC: ASM.
3. Bernstein J.M. Treatment of community-acquired pneumonia. IDSA guidelines. Infectious Diseases Society of America. Chest. 115:(3S):1999;9S-13S.
4. Deshpande L.M., Diekema D.J., Jones R.N. Comparative activity of clinafloxacin and nine other comparator compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagn Microbiol Infect Dis. 35:1999;81-88.
5. DiPersio J. R., Jones, R. N., Barrett, T., Doern, G. V., & Pfaller, M. A. (1998). Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: Report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 32, 131-135.
6. Doern, G. V., Jones, R. N., Pfaller, M. A., Kugler, K., & The SENTRY Participants Group (1999). Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: Antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother 43, 385-389.
7. Doern G.V., Pfaller M.A., Erwin M.E., Brueggemann A.B., Jones R.N. The prevalence of fluorqouinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 32:1998;313-316.
8. Hooper D.C. Expanding uses of fluoroquinolones Opportunities and challenges. Ann Int Med. 129:1998;908-910.
9. Jones, R. N., Ballow, C. H., Schentag, J., Johnson, D. M., Deinhart, J. A., & the SPAR Study Group. (1998). In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn Microbiol Infect Dis 31, 313-325.
10. Jones R.N., Wilson W.R. Epidemiology, laboratory detection, and therapy of penicillin-resistant streptococcal infections. Diagn Microbiol Infect Dis. 31:1998;453-459.
11. Lark R.L., Chenworth C. Antimicrobial resistance in community-acquired respiratory tract pathogens. Comprehensive Ther. 25:1999;20-29.
12. National Committee for Clinical Laboratory Standards (1997). Methods for dilution antimicrobial tests for bacterial that grow aerobically. Approved standard M7-A4. Wayne, PA: NCCLS.
13. National Committee for Clinical Laboratory Standards (1999). Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S9. Wayne, PA: NCCLS.
14. Plouffe J.F., Breiman R.F., Facklam R.R. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. J Am Med Assoc. 275:1996;194-198.
15. Sader H.S., Jones R.N., Gales A.C., Winokur P., Kugler K.C., Pfaller M.A., Doern G.V. Antimicrobial susceptibility patterns for pathogens isolates from patients in Latin American medical centers with a diagnosis of pneumonia analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin American Study Group. Diagn Microbiol Infect Dis. 32:1998;289-301.
16. Thornsberry C., Jones M.E., Hickey M.C., Mauritz Y., Kahn J., Sahm D.F. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother. 44:1999;749-759.